Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06325046 · ClinicalTrials.gov registry record · NA
Adaptive Radiation Therapy (ART) Stereotactic Ablative Body Radiotherapy (SABR) for Primary Localized Prostate Cancer
A NA study of Stage III Prostate Cancer AJCC v8 and Stage II Prostate Cancer AJCC v8, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- NA
- Development phase
- 144
- Enrollment target
- 5
- Study locations
NCT06325046: Recruiting NA study of Stage III Prostate Cancer AJCC v8 and Stage II Prostate Cancer AJCC v8, sponsored by Mayo Clinic.
NCT06325046 is a NA study of Stage III Prostate Cancer AJCC v8 and Stage II Prostate Cancer AJCC v8 that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 144 participants, below the 244-participant average among 28 other Stage III Prostate Cancer AJCC v8 trials with a reported enrollment target (41% lower). The trial reports 5 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06325046, a NA study of Stage III Prostate Cancer AJCC v8 and Stage II Prostate Cancer AJCC v8, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- NA
- Development phase
- 144 participants
- Enrollment target
- 5
- Study locations
Study Summary
This clinical trial evaluates changes in quality of life after two treatments with near margin-less adaptive radiation therapy (ART) compared to five treatments with standard stereotactic ablative body radiotherapy (SABR) in patients with prostate cancer that has not spread to other parts of the body (localized). ART is a type of radiation therapy that uses information gathered during the treatment cycle to inform, guide, and alter future radiation treatments with respect to location and dose. It may be able to deliver radiation to the site of disease over a shorter time and with smaller margins (less treatment delivered to nearby healthy tissues). SABR is a type of external radiation therapy that uses special equipment to position a patient and precisely deliver radiation to tumors in the body (except the brain). The total dose of radiation is divided into smaller doses given over several days. This type of radiation therapy helps spare normal tissue. Shorter duration near margin-less ART may be just as effective at treating patients with localized prostate cancer but have less quality of life side effects than standard SABR.
Primary Outcome
Will be assessed using the Expanded Prostate Cancer Index Composite (EPIC)-26. The EPIC-26 consists of 13 questions answered on a variety of scales, such as 1-5 where 1=very poor and 5=very good.
Conditions Studied
Interventions
- PROCEDURE Computed Tomography
- PROCEDURE Magnetic Resonance Imaging
- PROCEDURE Cone-Beam Computed Tomography
- PROCEDURE Stereotactic Ablative Radiotherapy
- RADIATION Image-Guided Adaptive Radiation Therapy
Study Locations (5)
Minnesota
- Mayo Clinic Health System in Albert Lea - Albert Lea
- Mayo Clinic Health System-Mankato - Mankato
- Mayo Clinic in Rochester - Rochester
Wisconsin
- Mayo Clinic Health System-Eau Claire - Eau Claire
- Mayo Clinic Health System-Franciscan Healthcare - La Crosse
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 144 participants |
| Start Date | 2024-08-15 |
| Est. Completion | 2026-08 |
| Phase | NA |
What NCT06325046 shows while recruiting
NCT06325046 is an interventional study that assigns participants to a tested intervention. The registered 144 participants enrollment target is mid-sized for trials with a published cap, below the 244-participant average among 28 other Stage III Prostate Cancer AJCC v8 trials with a reported enrollment target (41% lower).
The record links to 4 conditions, with Stage III Prostate Cancer AJCC v8 appearing as the primary indexed condition, and to 5 interventions - of which Computed Tomography is the first listed.
NCT06325046 lists 5 locations in 2 states (Minnesota, Wisconsin).
Frequently Asked Questions
What is clinical trial NCT06325046 about?
NCT06325046 is a clinical study titled "Adaptive Radiation Therapy (ART) Stereotactic Ablative Body Radiotherapy (SABR) for Primary Localized Prostate Cancer". This clinical trial evaluates changes in quality of life after two treatments with near margin-less adaptive radiation therapy (ART) compared to five treatments with standard stereotactic ablative body radiotherapy (SABR) in patients with prostate cancer that has not spread to other parts of the bod...
What is the current status of trial NCT06325046?
This trial is currently recruiting. It is a NA study. The enrollment target is 144 participants. The study started on 2024-08-15. Estimated completion is 2026-08.
What conditions does trial NCT06325046 study?
This clinical trial studies the following conditions: Stage III Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage I Prostate Cancer AJCC v8, Localized Prostate Adenocarcinoma.
What interventions are being tested in trial NCT06325046?
The interventions under investigation include: Computed Tomography (PROCEDURE), Magnetic Resonance Imaging (PROCEDURE), Cone-Beam Computed Tomography (PROCEDURE), Stereotactic Ablative Radiotherapy (PROCEDURE), Image-Guided Adaptive Radiation Therapy (RADIATION).
Who is sponsoring clinical trial NCT06325046?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06325046 being conducted?
This trial has 5 study locations across Minnesota, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stage III Prostate Cancer AJCC v8
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06325046's enrollment target sits among peer trials
144 10th of 28 higher than 19 of 28 other Stage III Prostate Cancer AJCC v8 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Stage III Prostate Cancer AJCC v8 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Golf Recreational Exercise for Enhanced Survivorship in Prostate Cancer Survivors
RECRUITING · NA
-
High Dose-Rate Brachytherapy and Stereotactic Body Radiotherapy for the Treatment of Prostate Adenocarcinoma
RECRUITING · NA
-
Accuracy of 18F-rhPSMA-7.3 PET/ MRI for Prediction of Lymph Node Metastasis in Localized High-Risk Prostate Cancer
RECRUITING · NA
-
Computed Tomography-Guided Stereotactic Body Radiation Therapy With Intrafraction Motion Monitoring for the Treatment of Localized Prostate Cancer, ILLUSION Trial
RECRUITING · NA
-
Peer Navigation for the Support of Metastatic Prostate Cancer Patients Undergoing Genetic Evaluation
RECRUITING · NA
-
Proton Radiation Therapy for the Treatment of Patients With High Risk Prostate Cancer
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01861106 · 144 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations
- NCT03482245 · 144 participants · NA
The Role of Circadian Clock Proteins in Innate and Adaptive Immunity
- NCT03504683 · 144 participants · NA
MEAL TIMING Study: Effect of Time-Restricted Feeding on 24-hour Glycemic Control, Blood Pressure, and Cardiovascular Disease Risk Factors in Adults With Prediabetes
- NCT03905603 · 144 participants · Early Phase 1
Relative Contributions of Predictors of Hyperandrogenism in Older vs. Young Women With PCOS
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI